Alzamend Neuro, Inc. ALZN
the context requires otherwise, references to the "Company," "Alzamend," "we," "our company"
and "us" refer to Alzamend Neuro, Inc., a Delaware corporation and its subsidiary.
company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar
disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"). With
Last close
1.13
2026-10-23
Market cap
$5.4M
2026-04-30 share count
52-week range
0.84 - 2.68
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-2.63
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D | $3.6M | $1.4M | $6.5M | $7.4M | $5.2M | $1.3M | $1.1M | — |
| SG&A | $5.1M | $3.1M | $3.5M | $7.4M | $7.1M | $3.6M | $3.4M | — |
| Total operating expenses | $8.8M | $4.5M | $9.9M | $14.9M | $12.3M | $5.0M | $4.4M | — |
| Operating income | -$8.8M | -$4.5M | -$9.9M | -$14.9M | -$12.3M | -$5.0M | -$4.4M | — |
| Interest expense | $6.6K | $18.0K | $10.1K | $7.7K | $46.5K | $142.4K | $13.9K | — |
| Pre-tax income | -$8.8M | -$4.5M | -$9.9M | -$14.9M | -$12.4M | -$5.0M | -$4.4M | — |
| Net income | -$8.8M | -$4.5M | -$9.9M | -$14.9M | -$12.4M | -$5.0M | -$4.4M | — |
| EPS, basic | -2.63 | -11.32 | -132.33 | -22.89 | -0.14 | — | — | — |
| EPS, diluted | -2.63 | -11.32 | -132.33 | -22.89 | -0.14 | -0.07 | -0.06 | — |
| Shares, diluted (wtd. avg.) | 3.3M | 450,799 | 74,174 | 650,126 | 89.1M | 72.7M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $710.7K | $3.9M | $376.0K | $5.1M | $14.1M | $1.9M | $90.3K | $42.6K |
| Total current assets | $1.8M | $4.2M | $455.2K | $5.8M | $14.4M | $2.9M | $1.8M | — |
| Property, plant and equipment | $314.9K | $425.6K | $176.3K | $79.8K | $102.9K | — | — | — |
| Total assets | $2.1M | $4.6M | $631.6K | $5.9M | $14.5M | $2.9M | $1.8M | — |
| Accounts payable | $1.3M | $634.8K | $2.9M | $2.9M | $1.2M | $503.6K | $929.6K | — |
| Total current liabilities | — | — | — | $2.9M | $1.2M | $899.6K | $992.3K | — |
| Total liabilities | $1.3M | $634.8K | $3.2M | $2.9M | $1.2M | $899.6K | — | — |
| Retained earnings | -$67.3M | -$58.5M | -$54.0M | -$44.1M | -$29.2M | -$16.8M | -$11.8M | — |
| Total equity | $2.2M | $4.0M | -$2.6M | $3.0M | $13.4M | $2.0M | $821.7K | $316.9K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.1M | -$6.6M | -$8.3M | -$8.9M | -$6.6M | -$2.7M | -$2.3M | — |
| Depreciation and amortisation | $110.7K | $50.7K | $50.7K | $23.1K | $3.5K | — | — | — |
| Stock-based compensation | $707.5K | $325.1K | $955.6K | $3.6M | $4.4M | $2.0M | $1.8M | — |
| Investing cash flow | — | -$300.0K | -$147.2K | — | -$106.5K | $100.9K | $105.0K | — |
| Financing cash flow | $4.8M | $10.4M | $3.7M | $200 | $18.9M | $4.5M | $2.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001214659-26-008832.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$4.4M | -$5.0M | -$12.4M | -$14.9M | -$9.9M | -$4.5M | -$8.8M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Delisting notice Item 3.01
- Material agreement signed Item 1.01
- Other event Item 8.01
- Charter or fiscal year changed Item 5.03
- Unregistered share sale Item 3.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |